Skip to main content
. 2016 Mar 14;6(1):20–28. doi: 10.1016/j.kisu.2016.01.004

Figure 1.

Figure 1

A comparison of hyperkalemia rates in patients with CHF in clinical trials and in the real-world setting. The left bars in the 2 panels depict hyperkalemia rates in RALES (Randomized Aldactone Evaluation Study)31 and in a clinical study after the publication of RALES.29 The right bars in the two panels depict the hyperkalemia rates in the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) study32 and an analysis following the application of the RALES trial protocol to the care of 104 patients, who were identified as being started on spironolactone for HF after prerelease of the RALES trial.30 Clearly, hyperkalemia rates are higher in congestive heart failure patients on mineralocorticoid receptor antagonist therapy in a real-world clinical setting.